clinical trial · NCT07702955
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
Kangabio AUSTRALIA LTD PTY·phase1·not yet recruiting·n = 85
Advanced or Metastatic Solid TumorsKGX105 injection
brief summary
This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.
started
Aug 1, 2026
primary completion
Sep 1, 2028
completion
Nov 1, 2028
last updated
Jul 21, 2026
official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single-Agent KGX105 in Participants With Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol